878 related articles for article (PubMed ID: 17128529)
1. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
2. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
3. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
6. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
[TBL] [Abstract][Full Text] [Related]
8. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
9. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
11. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
12. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
13. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
15. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
17. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
18. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia.
Gupta S; Singh PK; Bhatt ML; Pant MC; Gupta R; Negi MP
Biosci Trends; 2010 Oct; 4(5):273-8. PubMed ID: 21068482
[TBL] [Abstract][Full Text] [Related]
20. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
Morstyn G; Foote M; Perkins D; Vincent M
Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
